SYN Synthetic Biologics Dashboard

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Company profile

Ticker

SYN

Exchange

AMEX

Website

www.syntheticbiologics.com

CEO

Steven A. Shallcross

Incorporated

Nevada

Location

Maryland

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Warner Chilcott ...

Former names

ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD MEDICAL TECHNOLOGIES INC, SHEFFIELD PHARMACEUTICALS INC

SEC CIK

0000894158

Corporate docs

Articles of Incorporation & Bylaws

IRS number

133808303

SYN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

1 Aug 21

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

Synthetic Biologics Files 2 U.S. Patent Applications Titled, 'MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS', 'ALKALINE PHOSPHATASE FORMULATIONS'

22 Jul 21

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=7288&p=146&f=G&l=50&d=PG01&S1=20210722.PD.&OS=PD/20210722&Rhttps://appft.

Synthetic Biologics Says Patient Dosing And Observation Has Been Completed In Phase 1 Study Of SYN-020

29 Jun 21

Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet

24 Stocks Moving in Friday's Pre-Market Session

4 Jun 21

26 Stocks Moving in Wednesday's Pre-Market Session

12 May 21

Press releases

Pro users get this 30m faster

Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

29 Jun 21

ROCKVILLE, Md., June 29, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

26 May 21

ROCKVILLE, Md., May 26, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results

5 May 21

ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI)

Synthetic Biologics, Inc. to Host Earnings Call

5 May 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

5 May 21

2 Aug 21

31 Dec 21

Financial summary

Financial statements Chart SYN financial data

Quarter (USD)	Mar 21	Dec 20	Sep 20	Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	76.89M	76.89M	76.89M	76.89M	76.89M	76.89M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	845.67K	805.75K	1.11M	878K
Cash used (since last report)	n/a	n/a	3.45M	3.29M	4.53M	3.59M
Cash remaining	n/a	n/a	73.43M	73.6M	72.36M	73.3M
Runway (months of cash)	n/a	n/a	86.8	91.3	65.2	83.5

Beta Read what these cash burn values mean

Recent insider trades

SYN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 May 21	Steven A Shallcross	Common Stock	Buy	Aquire P	No	No	0.4919	50,000	24.6K	100,000
30 Dec 20	Steven A Shallcross	Stock Options Common Stock	Grant	Aquire A	No	No	0.417	450,000	187.65K	450,000
30 Dec 20	John J Monahan	Stock Options Common Stock	Grant	Aquire A	No	No	0.417	150,000	62.55K	150,000
30 Dec 20	Wolf Jeffrey Alan	Stock Options Common Stock	Grant	Aquire A	No	No	0.417	150,000	62.55K	150,000
30 Dec 20	Kraws Jeffrey J	Stock Options Common Stock	Grant	Aquire A	No	No	0.417	150,000	62.55K	150,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

SYN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

9.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	34	24	+41.7%
Opened positions	14	5	+180.0%
Closed positions	4	4	–
Increased positions	11	5	+120.0%
Reduced positions	1	3	-66.7%

13F shares	Current	Prev Q	Change
Total value	8.29M	2.72M	+205.3%
Total shares	11.87M	7.16M	+65.8%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BLK Blackrock	2.35M	$1.6M	+6046.0%
Custodian Ventures	2.22M	$1.96M	+13.2%
Vanguard	2.01M	$1.37M	+5436.1%
Iroquois Capital Management	1.13M	$433K	0.0%
MSD Partners	960.68K	$655K	NEW
Geode Capital Management	860.42K	$586K	+4779.6%
UBS UBS Group AG - Registered Shares	576.93K	$393K	NEW
Citadel Advisors	539.12K	$368K	NEW
VIRT Virtu Financial	466.7K	$318K	+347.1%
NTRS Northern Trust	246.54K	$168K	+1706.7%

Largest transactions	Shares	Bought/sold	Change
BLK Blackrock	2.35M	+2.31M	+6046.0%
Hudson Bay Capital Management	0	-2.22M	EXIT
Vanguard	2.01M	+1.98M	+5436.1%
Renaissance Technologies	0	-1.24M	EXIT
MSD Partners	960.68K	+960.68K	NEW
Geode Capital Management	860.42K	+842.79K	+4779.6%
UBS UBS Group AG - Registered Shares	576.93K	+576.93K	NEW
Citadel Advisors	539.12K	+539.12K	NEW
VIRT Virtu Financial	466.7K	+362.32K	+347.1%
Custodian Ventures	2.22M	+260K	+13.2%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Qualigen Therapeutics • Immune Therapeutics

Management Discussion

General and administrative expenses increased by 2% to approximately $1.42 million for the three months ended March 31, 2021, from approximately $1.39 million for the three months ended March 31, 2020. This increase is primarily due to higher insurance costs, audit fees, and legal costs offset by a reduction in patent related legal fees, consulting fees and travel expense. The charge related to stock-based compensation expense was $82,000 for the three months ended March 31, 2021, compared to $65,000 the three months ended March 31, 2020.
Research and development expenses decreased by 32% to approximately $1.1 million for the three months ended March 31, 2021, from approximately $1.6 million for the three months ended March 31, 2020. This decrease is primarily the result of lower indirect program costs for the three months ended March 31, 2021, including salary and related expense reductions, a decrease in manufacturing costs for SYN-020 and market research. In addition, as a result of the global COVID-19 pandemic, our clinical development partner (Washington University) reduced their operating capacity during 2021 to include only essential activities as part of their pandemic response, which delayed the start of our clinical trial, resulting in lower clinical trial expenses for the quarter. The research and development costs incurred during the quarter were primarily related to our Phase 1a clinical trial of SYN-020 and the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients. We anticipate research and development expense to increase as our ongoing clinical trials continue to enroll patients. The charge related to stock-based compensation expense was $19,000 for the three months ended March 31, 2021, compared to $18,000 related to stock-based compensation expense for the three months ended March 31, 2020.
Other income was $347 for the three months ended March 31, 2021, compared to other income of $38,000 for the three months ended March 31, 2020. Other income for the three months ended March 31, 2021 and 2020 is primarily comprised of interest income.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abated, accurately, aforementioned, AGP, April, ATM, Australia, authorized, began, begun, biotechnology, blocker, book, clause, climate, competitive, declined, discernable, disconnected, extreme, facilitating, facility, fire, gluten, hereof, inability, inconsistent, induce, inducement, inflated, instability, insufficient, issuable, law, leave, liver, lose, losing, MAD, Nevada, past, pathway, play, political, Practice, predominantly, prevalent, prohibit, put, reaction, remeasurement, restated, role, Secretary, squeeze, stability, steadily, stemming, streamlined, superior, terrorism, Topic, underway, unissued, unpaid, volume, war, weather

Removed: abdominal, absenteeism, accomplished, achieve, acted, adaptive, Aid, altogether, amending, amortized, assure, assured, avoid, baseline, beneficially, bloating, breath, Bulletin, capitalization, capsule, carryback, classification, cleared, collaborator, combined, communication, competing, composition, comprehensive, comprise, conclusion, confident, Confirmed, convene, criterion, decide, decision, deduct, deficiency, delisted, delisting, design, desire, diagnosed, difficult, dollar, doubt, downturn, economy, effort, eligibility, eligible, enable, enacted, enforcing, enrolling, establish, established, eventually, execute, expenditure, Exploratory, extend, fact, fail, fell, fewer, firm, fiscal, frequency, Fundamental, furlough, generating, geographic, group, Guide, halt, harmed, ill, impacting, implementing, Importantly, imposed, improvement, inclusive, infected, inform, infrastructure, intend, interruption, investigating, issuer, junior, large, light, limit, liquid, list, listed, longer, lot, manager, mandate, meaningful, Medically, medication, nationwide, noted, obtaining, occur, office, OTC, outlined, outlining, overhead, package, pain, parity, partial, participate, partnering, people, periodically, postponed, postponing, previously, proceeding, prospective, prove, proximity, pursuing, pursuit, quality, quotation, rapidly, receiving, recommence, recommended, recover, recoverability, recruit, recruiting, recruitment, redesigned, reflect, regain, registrational, Regulation, Relief, removal, removing, rescue, runway, satisfy, schedule, Science, screen, screened, screening, Section, securing, selected, serving, shelf, shipping, sooner, specifically, spend, spending, spent, sponsored, statin, stating, stool, substantially, successful, suffer, sustained, sweeping, temporarily, testing, timeline, transport, treating, twelve, unamortized, unexpected, unintended, utilization, utilize, vancomycin, variety, visit, weekly, widespread, wrong

From filing 10-Q 2021 Q1